Studying how the brain clears amyloid in Alzheimer's disease
Observes how the brain clears amyloid protein in people with memory decline.
Plain-language title generated from the registry record
Registry title: Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Key facts
- Where
- München, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT05059158, who can take part
Where in Germany
- Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU KlinikumsMünchen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ludwig-Maximilians - University of Munich
- Trial code
- NCT05059158
- Record updated
- 4 July 2025
- Original description
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.Read full original descriptionShow less
Amyloid-β Clearance Mechanisms: A Multi-modal Study on Lymphatic, Glymphatic and Blood-brain-barrier Function in Alzheimer's Disease
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
Inclusion: Diagnosis of amnestic MCI or AD dementia or clinical normal; Able to provide written informed consent; Unchanged pharmacotherapy within 4 days prior to the study specific assessments; Fluent in German.
Exclusion: Current alcohol, drug or medication abuse; History of severe traumatic brain injury within 3 months prior to inclusion; Unresolved malignancies within two years prior to inclusion; Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder; Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus; Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension; Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication; Severe current infections or other chronic or systemic disorders; Renal failure > stage 3 (GFR < 30 mL/min); Unable to give informed consent or has a legal guardian; Clinically relevant depression; Acute suicidality; Structural lesions of the basal ganglia or brain stem; Pregnancy; Other circumstances which preclude participation based on the investigator's judgement.